PL BioScience will be at the virtual Cell Therapy Manufacturing & Gene Therapy Congress 2020 Also this year from October 19 to 22, 2020 we will participate the international congress for Cell & Gene Therapy The year 2020 is a special year and we are glad to
The study performed with human Platelet Lysate (hPL) at the University of Miami showed an enhanced performance of manufactured IFP - MSCs under regulatory compliant conditions. The aim of the study was to proof the hypothesis: IFP-MSCs manufactured under these conditions do not need "ex-vivo priming
Fatal disadvantages of FBS shown The essay by Toni Lindl and Gerhard Gstraunthaler demonstrates the fatal disadvantages of Fetal Bovine Serum (FBS). The article published in the German scientific magazine 'Laborjournal' proposes a contemporary cell culture solution: Human Platelet Lysate (hPL). High reproducibility of trial results achieved
PL BioScience will be one of the exhibitors at the German Stem Cell Network (GSCN) Conference in Berlin. The GSCN aims to foster basic and applied stem cell research - so does the conference: Latest findings in stem cell biology will be covered. The conference will be held from
PL BioScience team participates in the AC² Innovation Award ceremony The PL BioScience team participated in the AC² Innovation Award ceremony in the historic city hall of Aachen. During the event, the winner of the award has been announced. PL BioScience was nominated as one of 5
PL BioScience is mentioned in the local newspaper ‘Aachener Zeitung’ one more time. Prior to the award ceremony on 6 June 2019, PL BioScience is presented in the recent press article as one of the five finalists. Our whole team is delighted about the appreciation and innovative strength
PL BioScience ensures its Good Manufacturing Practice throughout all process steps. We strive to offer high-quality services - from manufacture to the advise of our customers. For that reason, we established a holistic quality management system underlining our own commitment to quality. Recently, our Good Manufacturing
PL BioScience in 'Journal of the Chamber of Industry and Commerce Aachen' (Wirtschaftliche Nachrichten der Industrie- und Handelskammer Aachen) As one of the five finalists of the AC² Innovation Award 2019, we were able to present our patent-protected technologies to the Journal. The recent report pictures our novel cell
PL BioScience's technology in the local newspaper 'Aachener Zeitung'. Our platelet-based technology is one out of five 'technologies of the future' nominated for the AC² Innovation Award 2019 which honours one local laureate with unique innovative strength. 'Aachener Zeitung' has just presented the five finalists which have the opportunity
With our novel 2D and 3D cell culture media, we made it to the final round of the AC² Innovation Award 2019 for the Aachen region. Our technology based on human blood platelets is one out of five 'technologies of the future' nominated for the award.
"We demonstrate that human platelet lysate (hPL) can replace hS in macrophage cultivation [
The state-of-the-art workshop on the use of human Platelet Lysate for cell therapy was sponsored by PL BioScience. The meeting took place 22‐23 March 2018 in Zurich (Switzerland). Currently, the summarising Committee Report was published. The main stakeholders in the hPL area focused on the question: 'How can hPL further
Unique biopharma invention 'PL Matrix' as a model of successful knowledge transfer into economic application. Our 3D cell culture system PL Matrix is mentioned in a Case Study on the website of the Patent Marketing Agency PROvendis. Text abstract (report only available in German): "Die natürliche Wachstumsumgebung der Zellen
